Anti-CD20-Mediated B Cell Depletion Is Associated With Bone Preservation in Lymphoma Patients and Bone Mass Increase in Mice

Immunotherapy with anti-CD20-specific antibodies (rituximab), has become the standard of care for B cell lymphoproliferative disorders and many autoimmune diseases. In rheumatological patients the effect of rituximab on bone mass yielded conflicting results, while in lymphoma patients it has not yet...

Descripción completa

Detalles Bibliográficos
Autores principales: Kolomansky, Albert, Kaye, Irit, Ben-Califa, Nathalie, Gorodov, Anton, Awida, Zamzam, Sadovnic, Ofer, Ibrahim, Maria, Liron, Tamar, Hiram-Bab, Sahar, Oster, Howard S., Sarid, Nadav, Perry, Chava, Gabet, Yankel, Mittelman, Moshe, Neumann, Drorit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604358/
https://www.ncbi.nlm.nih.gov/pubmed/33193330
http://dx.doi.org/10.3389/fimmu.2020.561294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604358/
https://www.ncbi.nlm.nih.gov/pubmed/33193330
http://dx.doi.org/10.3389/fimmu.2020.561294

Ejemplares similares